ライフサイエンスコーパス: lamotrigine

1 at age 26 years or older (24% valproate, 22% lamotrigine).

2 py (phenytoin, carbamazepine, valproate, and lamotrigine).

3 crease in dollars spent on cocaine, favoring lamotrigine.

4 ed to another commonly used mood stabilizer, lamotrigine.

5 seizures was reported for carbamazepine and lamotrigine.

6 single dose of phenobarbital, phenytoin, or lamotrigine.

7 treated with ethosuximide, valproic acid, or lamotrigine.

8 ly decreased sensitivity to 8-bromo-cAMP and lamotrigine.

9 c symptoms was reduced with lithium, but not lamotrigine.

10 Folic acid seems to nullify the effect of lamotrigine.

11 MCM rate with increasing dose was found with lamotrigine.

12 apy exposure to valproate, carbamazepine and lamotrigine.

13 ilepsy through transport of carbamazepine or lamotrigine.

14 nificant advantage for carbamazepine against lamotrigine (0.91 [0.77-1.09]), topiramate (0.86 [0.72-1

15 significant difference between valproate and lamotrigine (1.25 [0.94-1.68]).

16 .15%), and 27 of the 1945 infants exposed to lamotrigine (1.39%).

17 valproate was significantly better than both lamotrigine (1.55 [1.07-2.24] and topiramate (1.89 [1.32

18 Lamotrigine, 10,11,-dihydro-10,11,-dihydroxy-carbamazepi

19 re discontinued, patients were randomized to lamotrigine (100-400 mg daily), lithium (0.8-1.1 mEq/L),

20 n to carbamazepine (105, 102-108; p=0.0015), lamotrigine (108, 105-110; p=0.0003), or phenytoin (108,

21 signed to treatment with ethosuximide (156), lamotrigine (149), or valproic acid (148) were similar w

22 Lamotrigine (2.31% in 4195 pregnancies) and levetiraceta

23 children exposed to carbamazepine (1/50) or lamotrigine (2/30).

24 igine (29%; odds ratio with ethosuximide vs. lamotrigine, 2.66; 95% CI, 1.65 to 4.28; odds ratio with

25 8; P=0.35) and were higher than the rate for lamotrigine (29%; odds ratio with ethosuximide vs. lamot

26 5 to 4.28; odds ratio with valproic acid vs. lamotrigine, 3.34; 95% CI, 2.06 to 5.42; P<0.001 for bot

27 e highest doses of valproate (300 mg/kg) and lamotrigine (30 mg/kg) also elevated ICSS thresholds, an

28 e voltage-gated Na+ and Ca2+ channel blocker lamotrigine (300 mg) abolished these changes.

29 4 test days involving the administration of lamotrigine, 300 mg by mouth, or placebo 2 hours prior t

30 rall (185 [86%] of 215; p=0.0404) and in the lamotrigine (59 [83%] of 71; p=0.0287) and valproate (38

31 mized to double-blind maintenance treatment (lamotrigine, 59 patients; lithium, 46 patients; and plac

32 mazepine (95% CI 1.9% to 3.5%) and 2.3% with lamotrigine (95% CI 1.8% to 3.1%).

33 nts lower than the score of those exposed to lamotrigine (95% confidence interval [CI], 3.1 to 14.6;

34 the mean IQ was 101 for children exposed to lamotrigine, 99 for those exposed to phenytoin, 98 for t

35 In this study, we tested the hypothesis that lamotrigine, a drug reported to inhibit glutamate releas

36 the first report of water samples containing lamotrigine, a relatively new drug used for the treatmen

37 Spontaneous suppressor mutations blocking lamotrigine activity mapped solely to the poorly charact

38 , the reduction in serum NfH levels based on lamotrigine adherence points to a possible neuroprotecti

39 showed no difference, however based on serum lamotrigine adherence there was significant decline in N

40 creased functional expression of R1648C, but lamotrigine also increased persistent sodium current evo

41 HA was more frequent with OD valproate than lamotrigine among those initiating treatment at age youn

42 Among the most cold sensitive was lamotrigine, an anticonvulsant drug.

43 participants were randomly assigned; 101 to lamotrigine and 101 to placebo.

44 ed to treatment (87 women and 33 men): 61 to lamotrigine and 59 to placebo.

45 with the binding of the anticonvulsant drug Lamotrigine and batrachotoxin are also seen in the modif

46 Lamotrigine and bupropion represent new treatments for n

47 m was to investigate transport of phenytoin, lamotrigine and carbamazepine by using seven in-vitro tr

48 -2.58 to 2.82]; p=0.931) for those receiving lamotrigine and folic acid.

49 or an AED that does not alter cP450 enzymes (lamotrigine and gabapentin) in monotherapy for 6 months

50 bipolar I disorder lost weight while taking lamotrigine and gained weight while taking lithium.

51 than a hundred aqueous samples analyzed and lamotrigine and its 2-N-glucuronide metabolite were most

52 channels up to 8-fold for the anticonvulsant lamotrigine and its congeners 227c89, 4030w92, and 619c8

53 ethod detection limits were 1 and 5 ng/L for lamotrigine and its metabolite, respectively.

54 treatment outcomes appeared to be better for lamotrigine and levetiracetam than for phenytoin.

55 d good seizure control and tolerability with lamotrigine and levetiracetam.

56 d to assess the efficacy and tolerability of lamotrigine and lithium compared with placebo for the pr

57 Both lamotrigine and lithium were superior to placebo at prol

58 Both lamotrigine and lithium were superior to placebo for the

59 The structurally different anticonvulsant lamotrigine and one of its derivatives have a binding si

60 ude the increase in plasma concentrations of lamotrigine and phenobarbital caused by valproic acid.

61 No dose effects were seen for lamotrigine and phenytoin.

62 bserve a reduction in NfH levels between the Lamotrigine and placebo arms, however, the reduction in

63 omparing absolute changes in NfH between the lamotrigine and placebo group showed no difference, howe

64 Lamotrigine and placebo groups were similar demographica

65 Lamotrigine and placebo were significantly better tolera

66 activity was confirmed on the pharmaceutical lamotrigine and the industrial solvent chlorobenzene, si

67 Lamotrigine and topiramate are also thought to possess b

68 in children in our study overall and in the lamotrigine and valproate groups.

69 oapoptotic action (phenobarbital, phenytoin, lamotrigine) and without proapoptotic action (levetirace

70 atment with atypical antipsychotics, MBP and lamotrigine, and H-FABP and lithium.

71 s the first detections of an antidepressant, lamotrigine, and its major metabolite (2-N-glucuronide),

72 ed than topiramate and more efficacious than lamotrigine, and should remain the drug of first choice

73 same enzymes (eg, tiagabine, valproic acid, lamotrigine, and topiramate).

74 in the United States: felbamate, gabapentin, lamotrigine, and topiramate.

75 ndomized double-blind trial of ethosuximide, lamotrigine, and valproate had short-term seizure outcom

76 We tested lacosamide, lamotrigine, and valproate in the rat ICSS test alone or

77 pproved for bipolar disorder (carbamazepine, lamotrigine, and valproate) are associated with an eleva

78 europrotection with tetrahydrocannabinol and lamotrigine are imminent; both will involve subjects wit

79 This work establishes lamotrigine as a widely available chemical probe of bact

80 y prescribed antiepileptic drugs (phenytoin, lamotrigine), as well as the cystic fibrosis transmembra

81 ith folic acid reducing the effectiveness of lamotrigine at 12 weeks.

82 ved a single 25-mg dose of immediate-release lamotrigine at the start of each period, with the brande

83 evere skin reactions; implicated agents were lamotrigine, azithromycin, carbamazepine, moxifloxacin,

84 nvulsant drugs phenytoin, carbamazepine, and lamotrigine block neuronal voltage-gated Na(+) channels,

85 verbal and executive functions compared with lamotrigine (but not carbamazepine or phenytoin).

86 Our data show that the TTC value of lamotrigine can be reached for a child at a daily consum

87 bilizing treatments of BD such as valproate, lamotrigine, carbamazepine, oxcarbazepine, antipsychotic

88 e proportion achieving a 12-month remission (lamotrigine-carbamazepine) is 0 (-8 to 7) and 5 (-3 to 1

89 zole, ketamine, memantine, N-acetylcysteine, lamotrigine, celecoxib, ondansetron) either in combinati

90 The pattern of lamotrigine changes during pregnancy in these women with

91 5 (-3 to 12), suggesting non-inferiority of lamotrigine compared with carbamazepine.

92 rogestagen contraceptive pill might decrease lamotrigine concentrations, which could worsen seizure c

93 t every 12 h (200-800 mg total, identical to lamotrigine dose prior to study enrolment); after each 1

94 the USA who were receiving immediate-release lamotrigine dosed at 100 mg, 200 mg, 300 mg, or 400 mg t

95 generic drugs) on-market, immediate-release lamotrigine drug products.

96 lso review the epilepsy literature on use of lamotrigine during pregnancy.

97 occurred more frequently with valproate than lamotrigine, especially if medication was started at age

98 induction of glucuronidation activity toward lamotrigine, ethinyl estradiol, chenodeoxycholic acid, a

99 By contrast, lamotrigine exacerbated the seizure phenotype.

100 Results were similar when lamotrigine-exposed infants were used as the reference g

101 CI 98-103, Cmax 90% CI 99-105), showing that lamotrigine exposures were equivalent between the generi

102 f action on sodium channels, a member of the lamotrigine family, R-(-)-2,4-diamino-6-(fluromethyl)-5-

103 rugs selected for discussion are gabapentin, lamotrigine, felbamate, vigabatrin, and topiramate.

104 ncourage clinicians and patients to consider lamotrigine for bipolar depression, but also to be aware

105 Lamotrigine, gabapentin, topiramate, and oxcarbazepine a

106 compounds (e.g., buproprion, carbamazepine, lamotrigine) generally were more persistent relative to

107 lume per year was -3.18 mL (SD -1.25) in the lamotrigine group and -2.48 mL (-0.97) in the placebo gr

108 analysed for the primary endpoint: 52 in the lamotrigine group and 56 in the placebo group.

109 More women in the valproate group than the lamotrigine group developed (OD) in the prospective (54%

110 More women in the valproate group than the lamotrigine group developed PCOS (9 vs 2%; p = 0.007).

111 nce were experienced more by patients in the lamotrigine group than the placebo group.

112 MCM rate for high-dose lamotrigine (>400 mg daily) was lower than the MCM rate

113 women more than 2 years after menarche (177 lamotrigine, (HA) 186 valproate) to exclude OD the confo

114 Patients receiving lamotrigine had lower depression ratings and Clinical Gl

115 ted that the standard sodium channel blocker lamotrigine had modest activity against Na(v)1.1, while

116 Lamotrigine had no effects on neuronal excitability of e

117 Subjects receiving lamotrigine had no significant reductions in calcium or

118 While lamotrigine has a favourable profile compared with valpr

119 Lamotrigine has been increasingly prescribed in pregnanc

120 Lamotrigine has been shown to be an effective treatment

121 d as anticonvulsants (notably, valproate and lamotrigine) have therapeutic effects in bipolar and rel

122 2; 95% confidence interval [CI], 1.11-1.80), lamotrigine (HR, 1.84; 95% CI, 1.43-2.37), oxcarbazepine

123 the clinically effective anticonvulsant drug lamotrigine (IC50=27.7 microM), a proposed neurotransmit

124 s similar to or different from valproate and lamotrigine in a model of reward and elevated mood.

125 effects of ethosuximide, valproic acid, and lamotrigine in children with newly diagnosed childhood a

126 Prescribing of lamotrigine in pregnancy has steadily increased and has

127 s present new data on serial serum levels of lamotrigine in pregnant patients on lamotrigine monother

128 available on the need for dosage changes for lamotrigine in pregnant women with bipolar disorder.

129 in prophylaxis of mania and depression, and lamotrigine in prophylaxis (relapse polarity unspecified

130 de and valproic acid are more effective than lamotrigine in the treatment of childhood absence epilep

131 safety and efficacy of a new anticonvulsant, lamotrigine, in adult patients with bipolar disorder who

132 Both phenytoin and lamotrigine increased functional expression of R1648C, b

133 However, lamotrigine increased the immediate mood-elevating effec

134 d safety of antidepressant augmentation with lamotrigine, inositol, and risperidone.

135 gned to open-label adjunctive treatment with lamotrigine, inositol, or risperidone for up to 16 weeks

136 son analyses of open-label augmentation with lamotrigine, inositol, or risperidone.

137 to assess whether the sodium-channel blocker lamotrigine is also neuroprotective in patients with sec

138 The results indicate that lamotrigine is an effective, well-tolerated maintenance

139 Lamotrigine is clinically better than carbamazepine, the

140 e for anticonvulsants such as divalproex and lamotrigine is less robust and there is much uncertainty

141 if combination therapy with quetiapine plus lamotrigine leads to greater improvement in depressive s

142 The change in serum lamotrigine levels in the postpartum period ranged from

143 In contrast, the new AEDs gabapentin, lamotrigine, levetiracetam, tiagabine, topiramate, vigab

144 atabase from two FDA registration studies of lamotrigine, lithium and placebo.

145 lysis was conducted to assess the effects of lamotrigine, lithium, and placebo administration on body

146 at week 52 were -4.2, +6.1, and -0.6 kg with lamotrigine, lithium, and placebo, respectively (lamotri

147 g) at week 52 were -0.5, +1.1, and +0.7 with lamotrigine, lithium, and placebo, respectively, with no

148 were suspect-screened for the anticonvulsant lamotrigine (LMG), its metabolites, and related compound

149 amazepine (CBZ) 0.43 (-0.19 to 1.05) p=0.17; lamotrigine (LTG) 0.31 (-0.38 to 1.00) p=0.38; levetirac

150 label data provide preliminary evidence that lamotrigine may be an effective treatment option for pat

151 Post hoc secondary analyses suggest that lamotrigine may be superior to inositol and risperidone

152 of AEDs; examples include the stimulation of lamotrigine metabolism by oral contraceptive steroids an

153 718 to carbamazepine monotherapy and 2198 to lamotrigine monotherapy.

154 evels of lamotrigine in pregnant patients on lamotrigine monotherapy.

155 ntibiotics (n = 25), ibuprofen (n = 15), and lamotrigine (n = 11).

156 mized to 12 months of valproate (n = 225) or lamotrigine (n = 222) therapy.

157 to degradation and that its human metabolite lamotrigine-N(2)-glucuronide (LMG-N2-G) is the actual so

158 mide (UCL 1684; K(+) channel antagonist) and lamotrigine (Na(+) channel antagonist) were found to sig

159 Neither lamotrigine nor carbamazepine was a substrate for P-gp i

160 Two detections for lamotrigine occurred in drinking water.

161 ints to a possible neuroprotective effect of lamotrigine on axonal degeneration.

162 The effect of lamotrigine on cerebral volume of patients with secondar

163 T-Na(V)1.1 and both mutant channels, whereas lamotrigine only increased surface expression of R1648C.

164 No P-gp interaction was observed for lamotrigine or carbamazepine in any of the seven validat

165 nt to one of the noninducing anticonvulsants lamotrigine or levetiracetam.

166 re similar whether patients were switched to lamotrigine or levetiracetam.

167 participants were pretreated with 300 mg of lamotrigine or placebo and then were given the same dose

168 :1) by an adaptive minimisation algorithm to lamotrigine or placebo and to folic acid or placebo.

169 IQs among children exposed to carbamazepine, lamotrigine, or phenytoin but not among those exposed to

170 atients were randomly assigned to valproate, lamotrigine, or topiramate between Jan 12, 1999, and Aug

171 exposed to an antiepileptic (carbamazepine, lamotrigine, or valproate) or not exposed to an antiepil

172 sion valproate was significantly better than lamotrigine overall (0.76 [0.62-0.94]), and for the subg

173 nalysis suggests that the use of gabapentin, lamotrigine, oxcarbazepine, and tiagabine, compared with

174 signed to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate.

175 signed to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate.

176 ytoin, and valproate than in those receiving lamotrigine (p = 0.008).

177 ving phenytoin compared with those receiving lamotrigine (p = 0.017).

178 carries a significantly higher MCM risk than lamotrigine (p=0.0001) and carbamazepine (p=0.0001) mono

179 ge younger than 26 years (44% valproate, 23% lamotrigine; p = 0.002) but was similar if treatment was

180 e post hoc (HA) analyses (36% valproate, 23% lamotrigine; p = 0.007).

181 (OD) in the prospective (54% valproate, 38% lamotrigine; p = 0.010) and the post hoc (HA) analyses (

182 oss four commonly used drugs (carbamazepine, lamotrigine, phenytoin and valproate).

183 tiepileptic drug monotherapy (carbamazepine, lamotrigine, phenytoin, or valproate) between October, 1

184 a single antiepileptic agent (carbamazepine, lamotrigine, phenytoin, or valproate) in a prospective,

185 sy receiving monotherapy (ie, carbamazepine, lamotrigine, phenytoin, or valproate) were enrolled from

186 er 12 weeks than quetiapine monotherapy plus lamotrigine placebo.

187 The combination of lamotrigine plus quetiapine potentially offers improved

188 Lamotrigine pretreatment prevented many of the BOLD sign

189 in to the noninducing drugs levetiracetam or lamotrigine produces rapid and clinically significant am

190 s received balanced doses of an oral generic lamotrigine product every 12 h (200-800 mg total, identi

191 omized participants, 49 (98%) received all 3 lamotrigine products and completed at least 3 pharmacoki

192 Disparate generic lamotrigine products in patients with epilepsy showed bi

193 ween two disparate generic immediate-release lamotrigine products in patients with epilepsy.

194 s study provides evidence that the disparate lamotrigine products studied are bioequivalent when test

195 Furthermore, the HCN channel agonist lamotrigine rescued the electrophysiological and cogniti

196 icantly better tolerated than carbamazepine (lamotrigine, RR 5.24, 1.07-26.32; placebo, RR 3.60, 1.04

197 fer from that of placebo over 24 months, but lamotrigine seemed to cause early volume loss that rever

198 pal slices, we found that the anticonvulsant lamotrigine selectively reduced action potential firing

199 s and observed a significant decrease in the lamotrigine-sensitive K(+) current, suggesting that the

200 Compared with the third trimester, lamotrigine serum concentration increased an average of

201 The most dramatic increase in lamotrigine serum level early after delivery occurred at

202 Lamotrigine serum samples were obtained from eight mothe

203 Lamotrigine significantly decreased ketamine-induced per

204 In lamotrigine subjects, 1 ABCB1 missense polymorphism (rs2

205 in amount of cocaine use by self-report with lamotrigine suggests that a standard treatment for bipol

206 ned via a website by minimisation to receive lamotrigine (target dose 400 mg/day) or placebo for 2 ye

207 All of the women were taking lamotrigine throughout pregnancy.

208 , the prevalence of SGA ranged from 7.3% for lamotrigine to 18.5% for topiramate.

209 tion factor IF2 and prevented the binding of lamotrigine to IF2 in vitro.

210 Addition of lamotrigine to quetiapine treatment improved outcomes.

211 rial that compared initiating treatment with lamotrigine, topiramate and valproate in patients diagno

212 s converge on the consensus effectiveness of lamotrigine, topiramate, valproate, aripiprazole, olanza

213 d hippocampal NaV1.6 protein levels, whereas lamotrigine treatment had no effect on either pyramidal

214 Lamotrigine treatment reduced the deterioration of the t

215 Lamotrigine treatment resulted in the rapid accumulation

216 wever, in an exploratory modelling analysis, lamotrigine treatment seemed to be associated with great

217 Lamotrigine trial in SPMS was a randomised control trial

218 AChE inhibitors (tiapride, amisulpride, and lamotrigine), used as antipsychotic medicines, were iden

219 trigine, lithium, and placebo, respectively (lamotrigine versus lithium and lithium versus placebo).

220 SR16 total score between the group receiving lamotrigine versus the placebo group at 12 weeks was -1.

221 poral lobe, 1.25, 1.06-1.47), and treatment (lamotrigine vs carbamazepine, 0.76, 0.61-0.95).

222 e time to intervention for any mood episode (lamotrigine vs placebo, P =.02; lithium vs placebo, P =.

223 However, the recovery rate with lamotrigine was 23.8%, whereas the recovery rates with i

224 In contrast to prior findings, high-dose lamotrigine was associated with fewer MCMs than all dose

225 In summary, lamotrigine was associated with limited therapeutic bene

226 In the second experiment, pretreatment with lamotrigine was compared with placebo to identify which

227 d, double-blind, placebo-controlled trial of lamotrigine was conducted in 120 outpatients with bipola

228 Lamotrigine was detected in 94% of all the wastewater sa

229 The most common adverse event reported for lamotrigine was headache.

230 not the result of translation inhibition, as lamotrigine was incapable of perturbing protein synthesi

231 open-label phase during which treatment with lamotrigine was initiated and other psychotropic drug re

232 Lamotrigine was selected as the antiepileptic drug of in

233 For time to treatment failure, lamotrigine was significantly better than carbamazepine

234 Lamotrigine was superior to placebo at prolonging the ti

235 Lamotrigine was taken once daily in doses ranging from 1

236 Lamotrigine was used as adjunctive therapy (N = 60) or m

237 iepileptic drugs and not currently receiving lamotrigine were enrolled between July 18, 2013, and Jan

238 e nonionic PCs (carbamazepine, caffeine, and lamotrigine) were detected at significantly higher conce

239 Treatment with lamotrigine, which inhibits presynaptic release of gluta

240 The related compound lamotrigine, which is a better anticonvulsant but weaker

241 0 to -1.37]; p=0.004) for patients receiving lamotrigine without folic acid compared with 0.12 ([-2.5

242 Primary outcome was whether lamotrigine would significantly reduce detectable serum